10/30/2019 12:00 AM EDT
Source: U.S. House of Representatives, Committee on Energy and Commerce. Published: 10/30/2019. This three-hour, 49-minute Congressional hearing focuses on maintaining the safety and quality of medications in the market, and the Food and Drug Administration (FDA)’s authority to regulate what is a complex and increasingly global supply chain. The statement of Janet Woodcock, MD, Director of the FDA Center for Drug Evaluation and Research (CDER), includes information about advanced manufacturing, including medical countermeasure manufacturing, and implications for national security. (Video or Multimedia)
No hay comentarios:
Publicar un comentario